{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:42:18Z","timestamp":1791078138553,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.lpm.2009.06.004","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T09:13:49Z","timestamp":1249377229000},"page":"1307-1313","source":"Crossref","is-referenced-by-count":8,"title":["Immunosuppression apr\u00e8s transplantation h\u00e9patique"],"prefix":"10.1016","volume":"38","author":[{"given":"Yvon","family":"Calmus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2009.06.004_bib1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0168-8278(03)00428-8","article-title":"Immunosuppressive therapy in liver transplantation","volume":"39","author":"Conti","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2009.06.004_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11010-007-9505-7","article-title":"cDNA microarray analysis of cyclosporin A (CsA)-treated human peripheral blood mononuclear cells reveal modulation of genes associated with apoptosis, cell-cycle regulation and DNA repair","volume":"304","author":"Bai\u00e3o","year":"2007","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.lpm.2009.06.004_bib3","doi-asserted-by":"crossref","unstructured":"Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; 18:CD005161.","DOI":"10.1002\/14651858.CD005161.pub2"},{"key":"10.1016\/j.lpm.2009.06.004_bib4","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.20707","article-title":"Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.lpm.2009.06.004_bib5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00007890-199802150-00030","article-title":"Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine","volume":"65","author":"Satterthwaite","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.lpm.2009.06.004_bib6","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/lt.21170","article-title":"Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation","volume":"13","author":"Cr\u00e9put","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.lpm.2009.06.004_bib7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/lt.21116","article-title":"Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients","volume":"13","author":"Morard","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.lpm.2009.06.004_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/lt.20124","article-title":"Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range","volume":"10","author":"Tredger","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.lpm.2009.06.004_bib9","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2009.06.004_bib10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/lt.21420","article-title":"Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"14","author":"Zimmerman","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.lpm.2009.06.004_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1600-6143.2006.01294.x","article-title":"Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival","volume":"6","author":"Kremers","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2009.06.004_bib12","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.lpm.2009.05.006","article-title":"Insuffisance r\u00e9nale apr\u00e8s transplantation h\u00e9patique","volume":"38","author":"Calmus","year":"2009","journal-title":"Press Med"},{"key":"10.1016\/j.lpm.2009.06.004_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0168-8278(00)00005-2","article-title":"De novo tumours after liver transplantation in adults. What is the actual risk ?","volume":"34","author":"Duvoux","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2009.06.004_bib14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semnephrol.2007.03.009","article-title":"Novel immunosuppression: small molecules and biologics","volume":"27","author":"Yabu","year":"2007","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.lpm.2009.06.004_bib15","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1600-6143.2006.01552.x","article-title":"FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia","volume":"6","author":"Salvadori","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2009.06.004_bib16","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/blood-2007-09-115030","article-title":"The specificity of JAK3 kinase inhibitors","volume":"111","author":"Changelian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.06.004_bib17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.transproceed.2004.12.157","article-title":"The impact of Campath 1H induction in adult liver allotransplantation","volume":"37","author":"Tryphonopoulos","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.lpm.2009.06.004_bib18","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"453","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2009.06.004_bib19","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/j.1600-6143.2007.01845.x","article-title":"A phase I\/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2009.06.004_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/157488706776876481","article-title":"Alefacept - a drug review","volume":"1","author":"Lev-Tov","year":"2006","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.lpm.2009.06.004_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ncpgasthep1070","article-title":"Mechanisms of disease: the evolving understanding of liver allograft rejection","volume":"5","author":"Eksteen","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.lpm.2009.06.004_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.trim.2007.01.005","article-title":"Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80\/86 blockade","volume":"17","author":"Chavez","year":"2007","journal-title":"Transpl Immunol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209003091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209003091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T21:03:27Z","timestamp":1558472607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498209003091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0755498209003091"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2009.06.004","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}